Skip to content

Treatment Response to Xiaflex for Men With Peyronie's Disease

Treatment Response to Xiaflex Based on Ultrasound Characterization of Plaque for Men With Peyronie's Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03774264
Enrollment
80
Registered
2018-12-12
Start date
2018-09-02
Completion date
2021-07-02
Last updated
2021-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peyronie Disease

Brief summary

The purpose of this research study is to develop a database of patients with Peyronie's disease who are treated at the University of Miami. The collected data will help the researchers to better understand Peyronie's disease and its response to therapy.

Interventions

None listed

Sponsors

Endo Pharmaceuticals
CollaboratorINDUSTRY
University of Miami
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * Able to provide informed consent * A stable relationship for ≥3 months * PD symptoms with evidence of stable disease as determined by the investigator * Penile curvature deformity of \>30° to \<90° * Has not had previous surgery for PD * Has not had previous therapy with Xiaflex for PD

Exclusion criteria

* Ventral plaque * Active phase PD * Actively on anticoagulation during time frame of injections * Aspirin 81mg will be eligible for therapy * Hour glass deformity * Previous allergic reaction to Xiaflex * Unwilling to participate * Medically unfit for sexual intercourse as deemed by the principal investigator * Patients scheduled to undergo an elective medical procedure during the investigation timeframe that will interfere with Xiaflex injection cycles as deemed by the PI

Design outcomes

Primary

MeasureTime frameDescription
Psychosexual changes in Peyronie's Disease Questionnaire (PDQ).52 weeksThe PDQ is highly responsive to treatment-related change in men with PD. It is self-administered, that measures psychosexual consequences after the presentation of PD. It is intended for men who have had vaginal intercourse in the past 3 months. The range of scores is from 0-24 points, with higher scores signifying greater psychosexual consequences from PD.
Penile pain evaluation in Peyronie's Disease Questionnaire (PDQ).52 weeksThe PDQ is highly responsive to treatment-related change in men with PD. It measures penile pain in patients with PD. It is intended for men who have had vaginal intercourse in the past 3 months, which evaluate the levels of pain or discomfort based on last erection or vaginal intercourse. The range of scores is from 0-30 points, with higher scores signifying greater penile pain or discomfort.
Goniometer measurement to determine degree of curvature of PD.52 weeksEvaluate the total degree change of curvature improvement after treatment with Xiaflex measured by goniometer, an instrument that measures the angle of the curvature to determine the degree of the PD.

Secondary

MeasureTime frameDescription
International Index of Erectile Function (IIEF) Scores52 weeksThe 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi- dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions, with a range of scores from 0-75, with lower scores signifying poorer erectile function.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026